Breakthrough drug may give kidney transplants to those previously turned away
NCT ID NCT04935177
First seen May 25, 2026 · Last updated Jun 16, 2026 · Updated 7 times
Summary
This study tested a drug called imlifidase in 64 people with very high antibody levels (cPRA ≥99.9%) who were waiting for a kidney transplant. The goal was to see if imlifidase could help them receive a kidney from a deceased donor and improve kidney function after one year compared to standard treatment. Participants were randomly assigned to get imlifidase or usual care, and kidney function was measured by eGFR.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner Health - University Medical Center - Phoenix
Phoenix, Arizona, 85006, United States
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Columbia University
New York, New York, 10032, United States
-
Georgetown Transplant Institute
Washington D.C., District of Columbia, 20007, United States
-
Hospital of the University of Pennsylvania, Penn Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
John Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Keck Hospital of University of Southern California (USC)
Los Angeles, California, 90033, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Phoenix
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Methodist Hospital Specialty and Transplant
San Antonio, Texas, 78229, United States
-
New York University (NYU) Langone Transplant Institute, NYU Langone Health
New York, New York, 10016, United States
-
New York-Presbyterian - Weill Cornell Medical Center
New York, New York, 10065, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Saint Barnabas Medical Center
Livingston, New Jersey, 07039, United States
-
Sutter Health - California Pacific Medical Center
San Francisco, California, 94115, United States
-
University of Alabama at Birmingham (UAB) Hospital
Birmingham, Alabama, 35249, United States
-
University of California San Francisco (UCSF) Medical Center
San Francisco, California, 94143-0780, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Minnesota Medical School
Minneapolis, Minnesota, 55455, United States
-
University of Washington Medical Center
Seattle, Washington, 98195, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.